Wechselwirkungen · Armisarte (previously Pemetrexed Actavis)
Armisarte 25 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-223770 · Präparat HOS-217236
In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4). If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastrointestinal toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) rofecoxib (HOS-113241) pemetrexed (HOS-113231)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-11T17:32:00Z · SHA-256 ad2d3dc28d4f7b5a98dcdc66bd5a74f1341b3c40625750424381ab6be3538c8d · Passage 1ae49fcc20f8a204e2a36b860e0a4f750dde041241287b576c3d415b4ef58fd1 · Zeichen 1633–2163 im Abschnitt